Mitoquinone Alleviates Donation after Cardiac Death Kidney Injury during Hypothermic Machine Perfusion in Rat Model
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241914772 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Anna Radajewska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Chemistry and Laboratory Hematology, Department of Medical Laboratory Diagnostics, Faculty of Pharmacy, Wroclaw Medical Universi…. Hauptthemen laut MEDLINE: Organ Preservation, Reperfusion Injury. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Poland.
Abstract (Originalsprache)
Transplanted organs are subjected to harmful conditions through stopping blood flow, hypothermic storage of the graft, and subsequent reperfusion. In particular, kidneys donated from patients after cardiac arrest (DCD) are classified as more vulnerable to ischemia–reperfusion injury (IRI). Hypothermic machine perfusion is proposed as a solution for better kidney storage before transplantation, and it is a good platform for additional graft treatment. Antioxidants have gained interest in regenerative medicine due to their ability to scavenge reactive oxygen species (ROS), which play a key role in IRI. We evaluated the effect of Mitoquinone (MitoQ), a strong mitochondria-targeted antioxidant, administered directly to the perfusing buffer. Rat kidneys were isolated, randomly classified into one of the following groups, donation after brainstem death (DBD), DCD, and DCD with MitoQ, and perfused for 22 hours with a hypothermic machine perfusion system. Subsequently, we detected levels of kidney injury (KIM-1) and oxidative stress (ROS/RNS, cytochrome C oxidase, and mitochondrial integrity) markers. We compared the activation of the apoptosis pathway (caspase 3 and 9), the concentration of phosphorylated Akt (pAkt), and the pAkt/total Akt ratio. MitoQ reduces KIM-1 concentration, total ROS/RNS, and the level of caspases. We observed a decrease in pAkt and the pAkt/total Akt ratio after drug administration. The length of warm ischemia time negatively impacts the graft condition. However, MitoQ added to the perfusing system as an ‘on pump’ therapy mitigates injury to the kidney before transplantation by inhibiting apoptosis and reducing ROS/RNS levels. We propose MitoQ as a potential drug for DCD graft preconditioning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Chemistry and Laboratory Hematology, Department of Medical Laboratory Diagnostics, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.
- Department of Anatomy, Physiology and Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
ORCID-Profile: Anna Krzywonos-Zawadzka, Agnieszka Olejnik, Iwona Bil-Lula
Förderung
- National Science Centre, Poland
Zitieren
APA
Radajewska, A., Szyller, J., Krzywonos-Zawadzka, A., Olejnik, A., Sawicki, G., & Bil-Lula, I. (2023). Mitoquinone Alleviates Donation after Cardiac Death Kidney Injury during Hypothermic Machine Perfusion in Rat Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914772
Vancouver
Radajewska A, Szyller J, Krzywonos-Zawadzka A, Olejnik A, Sawicki G, Bil-Lula I. Mitoquinone Alleviates Donation after Cardiac Death Kidney Injury during Hypothermic Machine Perfusion in Rat Model. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241914772
BibTeX
@article{Radajewska2023,
author = {Radajewska, Anna and Szyller, Jakub and Krzywonos-Zawadzka, Anna and Olejnik, Agnieszka and Sawicki, Grzegorz and Bil-Lula, Iwona},
title = {Mitoquinone Alleviates Donation after Cardiac Death Kidney Injury during Hypothermic Machine Perfusion in Rat Model},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241914772}
}
EUVIMED